TripAdvisor Inc. (TRIP) Falls 4.92% for February 08

Equities Staff |

One of the S&P 500’s big losers for Monday February 08 was TripAdvisor Inc. (TRIP). The company’s stock fell 4.92% to $55.50 on volume of 3.27 million shares.

The stock opened the day at 57.01 and traded between a low of $55.29 and a high of $57.84. The stock finished the day down $2.87 per share. TripAdvisor Inc. has an average daily volume of 2.07 million and a total float of 144.19 million shares. The 50-day SMA for TripAdvisor Inc. is $77.85 and its 200-day SMA is $77.99. The high for the stock over the last 52 weeks is $94.00 and the low is $57.29.

TripAdvisor Inc is an online travel company that provides access to the reviews and opinions of the millions of travelers users to plan and have the perfect trip.

TripAdvisor Inc. is centered in Newton, MA, and has 3,000 employees. Today’s trading day leaves the company with a market cap of $8 billion. The company has a P/S ratio of n/a, P/B ratio of 6.03, and a 40.7.

For a complete fundamental analysis analysis of TripAdvisor Inc., check out’s Stock Valuation Analysis report for TRIP. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…